

BIOGRAPHICAL SKETCH

NAME Min H. Kang		POSITION TITLE Tenure-track Assistant Professor	
EDUCATION/TRAINING (<i>Begin with baccalaureate or other initial professional education, and include postdoctoral training.</i>)			
INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
Chungbuk National University, South Korea	B.S.	1990	Pharmacy
University of Colorado, Denver, CO	Pharm.D.	1998	Clinical Pharmacy
National Cancer Institute, NIH, Bethesda, MD	Post-doc	1998-2001	Clinical Pharmacology

A. Positions and Honors.

Positions and Employment

Oct. 2001-Jan. 2002	Post-doctoral fellow, Research Center for Bioresource and Health, Chungbuk National University, South Korea
Feb. 2002-Mar. 2005	Research professor, Research Center for Bioresource and Health, Chungbuk National University, South Korea
Apr. 2005- Jun. 2008	Assistant professor of Pediatrics, Keck School of Medicine, University of Southern California and Childrens Hospital Los Angeles, Los Angeles, CA
Apr. 2005- Jun. 2008	Director, Leukemia Pre-Clinical Testing Laboratory, & Director, Pharmacology Laboratory USC-CHLA Institute of Pediatric Clinical Research
July 2008- present	Assistant professor and director of Pharmacology Core laboratory, School of Medicine, Texas Tech University Health Sciences Center

Other experience

March 2002- 2005	Lecturer, Sookmyung Women's University (South Korea)
April 2003 - 2005	Lecturer, Graduate School of Clinical Health Sciences, Ewha Women's University (South Korea)
Fall 2003	Lecturer, College of pharmacy Sookmyung Women's University (South Korea)
Spring 1999 - 2000	Pharm.D. Course Guest lecturer, School of Pharmacy, Shenandoah University, Winchester, Virginia

Honors and Awards:

NIH Clinical Pharmacology research fellowship grant, 1998-2001
Rho Chi Student Honor Society, 1998

B. Selected peer-reviewed publications, in chronological order (earliest to recent).

1. **Kang MH**, Figg WD, Dahut W. Taxanes in Hormone Refractory Prostate Cancer. *Cancer Practice* 1999;7(5): 270-272.
2. Chico I, **Kang MH**, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, Figg WD, Fojo T, Bates S. A Phase I study of infusional paclitaxel in combination with the Pgp antagonist PSC 833 (valsopodar). *Journal of Clinical Oncology* 2001;19:832-842.
3. Bates S, **Kang MH**, Bakke S, Meadows B, Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C, Robey R, Bergan R, Figg WD, Fojo T. A Phase I study of infusional vinblastine in combination with the Pgp antagonist PSC 833 (Valsopodar). *Cancer* 2001;92 (6):1577-1590.
4. **Kang MH**, Figg WD, Ando Y, Blagosklonny MV, Liewehr D, Fojo T, Bates SE. The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6 alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. *Clinical Cancer Res.* 2001;7:1610-1617.
5. Sandor V, Bakke S, Robey RW, **Kang MH**, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, and Bates SE. Phase I Trial of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228, NSC 630176), in Patients with Refractory Neoplasms. *Clin Cancer Res* 2002;8(3): 718-728.

Principal Investigator (Last, First, Middle): Kang, Min Hee

6. **Kang MH**, Lee MK. Advances in management of prostate cancer. *Korean Journal of Clinical Pharmacy*. 2001;11(2):78-88.
7. Bates SE, Chen C, Robey R, **Kang MH**, Figg WD, Fojo T. Reversal of multidrug resistance: lessons from clinical oncology. *Novartis Found Symp*. 2002;243:83-96; discussion 96-102, 180-5
8. Kim YM, Lee JJ, Yin SY, Kim Y, Lee JK, Yoon YP, **Kang MH**, Lee MK. Inhibitory effect of tributyltin on dopamine biosynthesis in PC12 cells. *Neuroscience Letters*. 2002;332:13-16.
9. Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, **Kang MH**, Figg WD, Wainer I, Chaissang C, Li MZ, Hawkins MJ. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. *J Exp Ther Oncol*. 2002;2(6):325-32.
10. Kim EI, Yin S, **Kang MH**, Hong JT, Oh KW and Lee MK. Reduction of serotonin content by tetrahydropapaveroline in murine mastocytoma P815 cells. *Neuroscience Letters*. 2003;339:131-134.
11. Lee JS, **Kang MH**, Kim MK, Lee MK, Chung SJ, Shim CS, and Chung YB. Pharmacokinetic modeling and simulation of the carrier-mediated hepatic transport of organic anions. *Yakhak Hoeji* 2003;47(2);110-119
12. Lee JJ, Kim YM, Yin SY, Park HD, **Kang MH**, Hong JT, Lee MK. Aggravation of L-DOPA-induced neurotoxicity by tetrahydropapaveroline in PC12 cells. *Biochem Pharmacol*. 2003;66(9):1787-95.
13. Bates SE, Bakke S, **Kang MH**, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, Merino M, Goldspiel B, Meadows B, Stein WD, Choyke P, Balis F, Figg WD, Fojo T. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. *Clin Cancer Res* 2004;10(14):4724-33.
14. **Kang MH**[†], Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned T, Maurer BJ, Lock RB, and Reynolds CP. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. *Blood*. 2007;110:2057-2066. [†]Correspondence
15. Reynolds CP, **Kang MH**, Keshelava N, Maurer BJ. Assessing combinations of cytotoxic agents using leukemia cell lines. *Curr Drug Targets*. 2007;8(6):765-71
16. **Kang MH**[†], Wan Z, Kang YH, Spoto R, Reynolds CP. Mechanism of Synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in Acute Lymphoblastic Leukemia Cell Lines: Mcl-1 Inactivation. *Journal of the Natl Cancer Inst*. 2008;100(8):580-95. [†]Correspondence
17. **Kang MH**, Reynolds CP. Bcl-2 inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy. *Clin Cancer Res* 2009;15:1126-1132.
18. **Kang MH**[†], Harutyunyan N, Hall CP, Papa RA, Lock RB. Methotrexate and Aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukemia and lymphoma. *Br J Haematol* 2009;145:389-393. [†]Correspondence
19. Morton C, Houghton PJ, Gorlick R, Kolb EA, Lock RB, Carol H, Keir ST, Reynolds CP, **Kang MH**, Maris JM, Billups C, Smith MA: Initial Testing of Aplidin by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer* 2009;53(3):509-12.
20. Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, **Kang MH**, Maris JM, Keir ST, Watkins A, Smith MA, Lock RB. Initial Testing of topotecan by the pediatric preclinical testing program. *Pediatr Blood Cancer* 2009 (in press).
21. Houghton PJ, Morton CL, **Kang MH**, Reynolds CP, Billups C, Favours E, Payne-Turner D, Tucker C, Smith MA, Evaluation of Cytarabine Against Ewing Sarcoma Xenografts by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer* 2009 (in press).
22. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Keir ST, Carol H, Lock R, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA. Initial Testing (Stage 1) of Mapatumumab (HGS-ETR1) by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer* 2009 (in press).

B. Other information considered essential for evaluation of your qualifications.

NCI Pediatric Preclinical Testing Program (PPTP) National Reference Laboratory **2004 - present**
Role: Co-Principal Investigator. Set up and administer robust in vitro cytotoxicity testing system to screen NCI investigational agents as a single drug/ combination with conventional chemotherapeutic agents.